Evidence map›Paper›PMID 41670725›Full record

ArticleCurrent microbiology2026

AddaVax-Adjuvanted Inactivated Vaccine Confers Protection Against Listeria monocytogenes Challenge in Mice.

Ye Wang, Lisi Wu, Chao Chen, Fanzeng Meng, Hongxiang Du, Xiang Chen, Xilong Kang, Hao Yao, Yuelan Yin, Xin'an Jiao

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ye WangJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China.
Lisi WuJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China.
Chao ChenJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China.
Fanzeng MengJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China.
Hongxiang DuJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China.
Xiang ChenJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China.
Xilong KangJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China.
Hao YaoJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China.
Yuelan YinJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China. yylan@yzu.edu.cn.
Xin'an JiaoJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China. jiao@yzu.edu.cn.

Funding

Jiangsu Agricultural Science and Technology Independent Innovation Funds CX(21)1004, CX(21)1049National Natural Science Foundation of China No. 32161133025Priority Academic Program Development of Jiangsu Higher Education Institutions Priority Academic Program Development of Jiangsu Higher Education Institutions
6 · The paper itself

Abstract

Listeria monocytogenes (Lm) is a facultative intracellular pathogen responsible for life-threatening listeriosis, characterized by high mortality rates. Currently, there is no vaccine available for the prevention or treatment of listeriosis. Here, we developed two adjuvanted inactivated vaccines and evaluated their safety, immunogenicity, and protective efficacy. The hypervirulent Lm strain XYSN was inactivated with β-propiolactone (BPL) and formulated with AddaVax or Alum to produce inactivated vaccines (ADIV and ALIV) respectively. Local reactogenicity and histopathological observations revealed no adverse reactions in a murine model. Humoral assays demonstrated both ADIV and ALIV induced higher antibody titers against Lm XYSN, with ADIV eliciting stronger cellular immune responses, as indicated by increased IL-17 and IFN-γ expression in spleen cells. Notably, ADIV conferred 83.3% protection against a lethal challenge with hypervirulent Lm strain, representing a 50% increase compared with the 33.3% protection achieved by ALIV. AddaVax adjuvant not only augmented humoral responses to inactivated bacterial cells but also elicited stronger cellular immune responses compared to Alum adjuvants, resulting in enhanced immune protection. This research offers insights into developing novel inactivated vaccines for listeriosis prevention, particularly beneficial for immunocompromised individuals.

Indexed as

Adjuvants, ImmunologicAdjuvants, VaccineBacterial VaccinesListeria monocytogenesListeriosisAnimalsAntibodies, BacterialDisease Models, AnimalFemaleImmunity, CellularInterferon-gammaMiceMice, Inbred BALB CVaccines, InactivatedAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, BacterialBacterial VaccinesInterferon-gammaVaccines, Inactivated

Identifiers

PMID41670725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.